Published 2025-01-01
“…Objective This study examined real-world treatment patterns and outcomes in patients with melanoma brain metastasis (MBM) treated with first-line immunotherapy consisting of nivolumab plus ipilimumab or anti-programmed death-1 (PD-1) monotherapy (nivolumab or pembrolizumab) or targeted therapy consisting of BRAF/MEK inhibitors.Design Retrospective chart review study.Setting
Academic medical centres, community hospitals and private practice offices.Participants Included patients diagnosed with melanoma with brain metastasis in the USA.Outcome measures The statistical analysis was descriptive in nature. …”
Get full text
Article